Table 4.
Incidence and AHR for cancer in patients in the Inso-Hyp, Inso-NonHyp, NonInso-Hyp, and NonInso-NonHyp groups
| Cancer (n, %) | Inso-Hyp vs. Inso-NonHyp | NonInso-Hyp vs. NonInso-NonHyp | Inso-Hyp vs. NonInso-Hyp | Inso-NonHyp vs. NonInso-NonHyp |
|---|---|---|---|---|
| All | 133 (3.12%) vs. 392 (2.30%) | 135 (3.03%) vs. 410 (2.30%) | 133 (3.12%) vs. 135 (3.03%) | 392 (2.30%) vs. 410 (2.30%) |
| Incidence | 4.73 vs. 3.29 | 5.41 vs. 3.62 | 4.73 vs. 5.41 | 3.29 vs. 3.62 |
| AHR (95% CI) | 1.49 (1.22-1.82)** | 1.68 (1.38-2.05)** | 1.04 (0.82-1.33) | 1.08 (0.94-1.25) |
| Oral cancer | 16 (0.38%) vs. 27 (0.16%) | 12 (0.27%) vs. 30 (0.17%) | 16 (0.38%) vs. 12 (0.27%) | 27 (0.16%) vs. 30 (0.17%) |
| Incidence | 0.56 vs. 0.22 | 0.47 vs. 0.26 | 0.56 vs. 0.47 | 0.22 vs. 0.26 |
| AHR (95% CI) | 2.44 (1.31-4.54)* | 1.92 (0.97-3.81) | 1.25 (0.58-2.68) | 0.93 (0.55-1.59) |
| Stomach cancer | 8 (0.19%) vs. 21 (0.12%) | 4 (0.09%) vs. 19 (0.11%) | 8 (0.19%) vs. 4 (0.09%) | 21 (0.12%) vs. 19 (0.11%) |
| Incidence | 0.28 vs. 0.17 | 0.16 vs. 0.17 | 0.28 vs. 0.16 | 0.17 vs. 0.17 |
| AHR (95% CI) | 1.60 (0.71-3.63) | 1.32 (0.44-4.02) | 2.32 (0.69-7.75) | 1.52 (0.81-2.87) |
| Colon cancer | 22 (0.52%) vs 72 (0.42%) | 19 (0.43%) vs. 75 (0.42%) | 22 (0.52%) vs. 19 (0.43%) | 72 (0.42%) vs. 75 (0.42%) |
| Incidence | 0.77 vs. 0.60 | 0.75 vs. 0.66 | 0.77 vs. 0.75 | 0.60 vs. 0.66 |
| AHR (95% CI) | 1.35 (0.83-2.17) | 1.25 (0.75-2.09) | 1.33 (0.71-2.49) | 1.13 (0.81-1.57) |
| Liver cancer | 16 (0.38%) vs. 42 (0.25%) | 22 (0.49%) vs. 40 (0.22%) | 16 (0.38%) vs. 22 (0.49%) | 42 (0.25%) vs. 40 (0.22%) |
| Incidence | 0.56 vs. 0.35 | 0.87 vs. 0.35 | 0.56 vs. 0.87 | 0.35 vs. 0.35 |
| AHR (95% CI) | 1.54 (0.86-2.74) | 2.53 (1.48-4.32)** | 0.84 (0.44-1.62) | 1.21 (0.78-1.88) |
| Lung cancer | 10 (0.23%) vs. 53 (0.31%) | 17 (0.38%) vs. 51 (0.29%) | 10 (0.23%) vs. 17 (0.38%) | 53 (0.31%) vs. 51 (0.29%) |
| Incidence | 0.35 vs. 0.44 | 0.67 vs. 0.45 | 0.35 vs. 0.67 | 0.44 vs. 0.45 |
| AHR (95% CI) | 0.83 (0.42-1.63) | 1.71 (0.98-3.00) | 0.65 (0.29-1.43) | 1.37 (0.93-2.03) |
| Skin cancer | 4 (0.09%) vs. 9 (0.05%) | _ | _ | 9 (0.05%) vs. 8 (0.04%) |
| Incidence | 0.14 vs. 0.07 | _ | _ | 0.07 vs. 0.07 |
| AHR (95% CI) | 1.94 (0.59-6.41) | _ | _ | 1.42 (0.54-3.75) |
| Breast cancera | 21 (1.02%) vs. 33 (0.40%) | 11 (0.61%) vs. 26 (0.36%) | 21 (1.02%) vs. 11 (0.61%) | 33 (0.40%) vs. 26 (0.36%) |
| Incidence | 1.53 vs. 0.57 | 1.06 vs. 0.56 | 1.56 vs. 1.06 | 0.57 vs. 0.56 |
| AHR (95% CI) | 2.85 (1.64-4.96)** | 2.08 (1.01-4.28)* | 1.67 (0.80-3.48) | 0.97 (0.54-1.64) |
| Corpus cancer | _ | _ | _ | 9 (0.05%) vs. 6 (0.03%) |
| Incidence | _ | _ | _ | 0.07 vs. 0.05 |
| AHR (95% CI) | _ | _ | _ | 1.04 (0.36-3.00) |
| Prostate cancer | 4 (0.09%) vs. 26 (0.15%) | 5 (0.11%) vs. 21 (0.12%) | 4 (0.09%) vs. 5 (0.11%) | 26 (0.15%) vs. 21 (0.12%) |
| Incidence | 0.14 vs. 0.22 | 0.20 vs. 0.18 | 0.14 vs. 0.20 | 0.22 vs. 0.18 |
| AHR (95% CI) | 0.70 (0.24-2.01) | 1.55 (0.57-4.23) | 0.94 (0.24-3.71) | 1.70 (0.94-3.05) |
Incidence, incidence density (1000 per person-years); AHR: adjusted hazard ratio using Cox proportional hazards regression model after controlling for age, sex, income, region, area, and CCI; *: p < .05; **: p < .001; ICD-O-3 codes: Oral cancer: C00-C06, C09-C10, C12-C14; Stomach cancer: C16; Colon cancer: C18-C21; Liver cancer: C22; Lung cancer: C33-C34; Skin cancer: C44; Breast cancer: C50; Corpus cancer: C54; Prostate cancer: C61. _: not applicable because of the sample size; a: only data of female patients were analyzed.